Viewing Study NCT05469061

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-24 @ 12:47 PM
Ignite Modification Date: 2026-02-03 @ 10:15 AM
Study NCT ID: NCT05469061
Status: UNKNOWN
Last Update Posted: 2022-07-21
First Post: 2022-06-08
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Tislelizumab in Combination With Chemotherapy for Conversion Therapy of Locally Nonresectable ESCC
Sponsor: The First Affiliated Hospital with Nanjing Medical University
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Esophageal Squamous Cell Carcinoma View
None Locally Advanced Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Drug: Tislelizumab View
None Chemotherapy View